HC Wainwright Cuts Adaptimmune Therapeutics (NASDAQ:ADAP) Price Target to $3.50

Adaptimmune Therapeutics (NASDAQ:ADAP) had its price objective decreased by HC Wainwright from $4.00 to $3.50 in a research note issued to investors on Thursday,Benzinga reports. HC Wainwright currently has a buy rating on the biotechnology company’s stock. HC Wainwright also issued estimates for Adaptimmune Therapeutics’ Q1 2025 earnings at ($0.18) EPS, Q2 2025 earnings at ($0.12) EPS, Q3 2025 earnings at ($0.12) EPS and Q4 2025 earnings at ($0.12) EPS.

Separately, StockNews.com raised Adaptimmune Therapeutics from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, August 13th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat.com, the company currently has an average rating of “Buy” and a consensus target price of $3.16.

Adaptimmune Therapeutics Stock Performance

ADAP opened at $0.59 on Thursday. The company has a current ratio of 3.09, a quick ratio of 3.09 and a debt-to-equity ratio of 0.26. The company has a fifty day moving average price of $0.88 and a two-hundred day moving average price of $1.03. The company has a market cap of $150.02 million, a P/E ratio of -2.67 and a beta of 2.26. Adaptimmune Therapeutics has a 1-year low of $0.42 and a 1-year high of $2.05.

Institutional Investors Weigh In On Adaptimmune Therapeutics

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Fullcircle Wealth LLC acquired a new position in Adaptimmune Therapeutics during the 3rd quarter valued at about $33,000. Vontobel Holding Ltd. lifted its holdings in shares of Adaptimmune Therapeutics by 230.8% in the third quarter. Vontobel Holding Ltd. now owns 43,000 shares of the biotechnology company’s stock valued at $41,000 after purchasing an additional 30,000 shares in the last quarter. Boulder Hill Capital Management LP purchased a new position in shares of Adaptimmune Therapeutics during the first quarter valued at approximately $143,000. GSA Capital Partners LLP purchased a new position in shares of Adaptimmune Therapeutics during the third quarter valued at approximately $95,000. Finally, Jane Street Group LLC grew its holdings in Adaptimmune Therapeutics by 130.4% during the third quarter. Jane Street Group LLC now owns 174,157 shares of the biotechnology company’s stock worth $166,000 after buying an additional 98,581 shares in the last quarter. Institutional investors and hedge funds own 31.37% of the company’s stock.

Adaptimmune Therapeutics Company Profile

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers.